The effect of 15-LOX-2 is attributed in part to its production of 15-HETE, which inhibits prostate cancer cell proliferation [24], [25], [26] through activation of peroxisome proliferator-activating receptor (PPAR)-γ [26], [28], [29]. Here, PPARG is linked to prostate cancer.